Author |
Topic: Imitrex (Read 610 times) |
|
Irma
Guest
|
Want to send this story to another AOL member? Click on the heart at the top of this window.
NovaDel Pharma Files U.S. Patents to Reformulate Market Leading Drugs for Migraines and Sleep
Quicker Than Normal Regulatory Path Predicted
FLEMINGTON, N.J., Sept. 30 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (OTC Bulletin Board: NVDL) said it filed U.S. patents enabling it to proceed with reformulation into lingual sprays of two clinically important drugs with current combined annual sales of over $2.4 Billion.
The company said the filings announced today cover lingually-delivered versions of the leading migraine remedy sumatriptan, marketed in the U.S. by Glaxo SmithKline (NYSE:GSK) under the brand name Imitrex(R), and zolpidem, the largest selling sleep-inducing agent, marketed in the U.S. by Sanofi (NYSE:SNY) as Ambien(R).
Both products are expected to benefit from the rapid onset of action provided by NovaDel's patented lingual delivery technology vs. the currently marketed pill formulations.
The technology utilizes the oral mucosa of the mouth to delivery drugs directly into the bloodstream, avoiding first pass liver metabolism. In the case of Ambien(R), NovaDel is predicting its lingual spray formulation will reduce onset of sleep to as little as 10 minutes, roughly half the time of the current pill, and it may also provide more clear-headed recovery.
With regard to Imitrex(R), NovaDel believes its lingual technology will at least match the 15-30 minutes to effective medication reportedly achieved by nasal formulations, but without irritation to the nasal passages. In pill form, Imitrex(R) requires 1-1.5 hours to achieve maximum serum concentration.
Novadel said it expects to begin pilot pharmacokinetic studies on at least one of the compounds within the next 90 days. The PK studies will confirm the ability of NovaDel's patented lingual spray technology to provide rapid therapeutic blood levels of the test compound, while avoiding the GI route of administration and first-pass liver effects. These features are inherent in NovaDel's patented method of drug delivery which allows drugs to enter the blood stream directly through the oral mucosa lining the mouth.
Imitrex(R) belongs to the triptan class of drugs which account for roughly $2.5 billion annual sales. They act on the brain's seratonin receptors to relieve the pain or discomfort of migraine and cluster headaches. NovaDel believes its proposed lingual formulation of sumatriptan will appeal not only to patients currently on Imitrex(R), but also users of other triptans who may find the lingual spray a preferred way to dose.
Drug-specific patent filings are the first step NovaDel routinely takes in readying itself for development of new products using its lingual delivery technology. The next steps are pilot and formal pharmacokinetic studies to determine the technology's utility with the target drug. Dose-ranging clinical trials would come next, followed by registration with the U.S. FDA under provisions of a 505(b)(2), an NDA which relies in part on data which has been previously generated by the drug's originator and in subsequent publications. The company indicated that review time for a 505(b)(2) is typically 10 months under PDUFA guidelines.
About NovaDel Pharma Inc.
NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary lingual spray technology delivery system offers the patient (i) fast onset of action; (ii) improved drug safety by reducing the required drug dosage and reducing side effects; (iii) improved patient convenience and compliance; and (iv) enhanced dosage reliability. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies.
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the ability to develop products (independently and through collaborative arrangements), and the ability to commercialize and obtain approval for products under development. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent Annual Report and Registration Statements, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings.
Contact:
Barry C. Cohen
VP New Business & New
Product Development
908.782-3431 x 31
NovaDel Pharma Inc.
Thomas Redington
203-222-7399
212 926-1733
tredington@redingtoninc.com
SOURCE NovaDel Pharma Inc.
CO: NovaDel Pharma Inc.
ST: New Jersey
SU:
http://www.prnewswire.com
09/30/2003 08:31 EDT
|
|
 IP Logged |
|
|
|
|
|
|
Home
Help
Search
Members
Member Map
Login
Register
Reply
Notify of replies
Send Topic
Print
Quote
Modify
Remove
test rss